The University of Southern Mississippi

The Aquila Digital Community
Doctoral Projects
Spring 5-12-2022

The Effect of VMAT2 Inhibitors on Tardive Dyskinesia Symptoms
in patients with Schizophrenia
Ada Kelly

Follow this and additional works at: https://aquila.usm.edu/dnp_capstone
Part of the Social and Behavioral Sciences Commons

Recommended Citation
Kelly, Ada, "The Effect of VMAT2 Inhibitors on Tardive Dyskinesia Symptoms in patients with
Schizophrenia" (2022). Doctoral Projects. 175.
https://aquila.usm.edu/dnp_capstone/175

This Dissertation/Thesis is brought to you for free and open access by The Aquila Digital Community. It has been
accepted for inclusion in Doctoral Projects by an authorized administrator of The Aquila Digital Community. For
more information, please contact Joshua.Cromwell@usm.edu.

THE EFFECT OF VMAT2 INHIBITORS ON TARDIVE DYSKINESIA
SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

by
Ada Kelly

A Doctoral Project
Submitted to the Graduate School,
the College of Nursing and Health Professions
and the School of Leadership and Advanced Nursing Practice
at The University of Southern Mississippi
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Nursing Practice

Approved by:
Dr. Carolyn Coleman, Committee Chair
Dr. Marti Jordan, Committee Member

May 2022

COPYRIGHT BY

Ada Kelly

2022

Published by the Graduate School

ABSTRACT
Prior to the FDA approval of VMAT2 inhibitors for the treatment of tardive
dyskinesia (TD), few concrete treatment options were available for TD. The most
common management strategy would include switching a patient from an FGA to an
SGA while discontinuing any anticholinergic medications the patient was currently
taking. Other options included changing, decreasing, or discontinuing the antipsychotic.
Augmenting stable antipsychotic regimens, however, may not be feasible in the
management of schizophrenia as antipsychotics are foundational in the treatment of
schizophrenia. A retrospective chart review was performed on 70 records that were
chosen through a convenience sample of patients being treated by one physician and two
nurse practitioners. The main intervention was the initiation of a VMAT2 inhibitor for the
treatment of TD, therefore no records were identified for comparison with the
intervention of initiation of a VMAT2 inhibitor. AIMs scores at four, eight, and twelve
weeks after VMAT2 initiation were identified. Fifteen (N=15) records were identified to
meet inclusion criteria for the DNP project. All records included patients between the
ages of 25 to 65 on an approved VMAT2 inhibitor for at least 90 days, with a diagnosis
within the DSM-V Schizophrenia Spectrum and other Psychotic Disorders of either
schizophrenia, schizophreniform disorder, schizotypal disorder, delusional disorder, or
schizoaffective disorder. The data from this DNP project shows that VMAT2 inhibitors
are very effective in reducing tardive dyskinesia symptoms based on the AIMS scale
scores and a statistically significant mean 4.27% decrease in AIMS scale scores overall in
the 12-week period, which is comparable to results obtained by previous studies.
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CHAPTER I - INTRODUCTION
Throughout the six editions of the Diagnostic and Statistical Manual of Mental
Disorders (DSM), the definition of schizophrenia has changed, yet three components
have remained the same. The three components that have remained within the root of all
the DSM editions are: (a) avolition, (b) the view that dissociative pathology is primary
and fundamental, and (c) the stress on reality distortion (Tandon et al., 2013).
Schizophrenia is a clinically diagnosed brain disorder with the hallmark symptom of
psychosis, which incorporates auditory hallucinations and delusions (American
Psychiatric Association [APA], 2013). According to the American Psychiatric
Association (2013), diagnostic criteria for schizophrenia is six-fold but must “include two
or more of the following: delusions, hallucinations, disorganized speech, grossly
disorganized or catatonic behavior, and negative symptoms such as a diminished
emotional expression or avolition; with each being present for a significant portion of
time during a one-month period” (p. 99), with the specification that either delusions,
hallucinations, or disorganized speech must be present (APA, 2013). Once the diagnosis
of schizophrenia has been determined, and the decision to initiate treatment has been
determined, treatment usually involves an antipsychotic medication.
Antipsychotics have been effectively used since the 1950s to treat schizophrenia,
however, these medications have various side effects, including movement disorders like
tardive dyskinesia (Bergman & Soares‐Weiser, 2018). Tardive dyskinesia (TD) is a
movement disorder that commonly affects the lips, tongue, jaw, face, periorbital areas,
trunks, and limbs (Ricciardi et al., 2019). According to the American Psychiatric
Association (2013), these symptoms generally develop in response to use of a neuroleptic
1

medication for at least a few months, persists despite discontinuing or changing the
medication, and must remain present for one month after discontinuation of the
medication, so as not to confuse TD with neuroleptic withdrawal emergent dyskinesia,
which usually lasts less than four to eight weeks and occurs after discontinuation, dosage
reduction, or medication change (Ward & Citrome, 2018). Several studies have identified
disruptions in dopamine D2 receptors as well as oxidative damage as potential causes of
TD, and although the literature indicates that second-generation antipsychotics (SGAs)
are less likely to precipitate TD than first-generation antipsychotics (FGAs), the literature
is still controversial (Ricciardi et al., 2019). As noted by Ricciardi et al., (2019), “equal
rates of TD have been reported for SGA and FGA treatments in randomized controlled
trials” (p. 389). According to Vasan and Padhy (2021), the average prevalence of TD is
20% of all individuals treated with FGAs, which differs significantly from the mean
prevalence rates noted by Ricciardi et al. (2019), of 21% for patients being treated with
an SGA and 30% for patients being treated with an FGA. According to the American
Academy of Neurology (AAN, 2013), the prevalence of TD in outpatients with
schizophrenia being treated with neuroleptics is 30%. According to Carroll and Irwin
(2019) “In 2017, the global mean prevalence of TD among all patients taking
antipsychotics was estimated to be 25.3%” (p. 811). Carroll and Irwin (2019) also note
that the incidence rate for adults receiving FGAs or SGAs ranges from less than 1% to
42% annually with elderly patients being five times more likely to get TD than younger
patients. These differing prevalence rates bring to the forefront the reality that all
antipsychotics can be associated with TD development, and the recommended treatment
guidelines suggesting withdrawal of antipsychotic medications or reduction in dosage,
2

are not clinically possible for patients with schizophrenia as these medications are
integral for controlling their psychotic symptoms and preventing relapse (Bergman et al.,
2017).
As noted by Ward and Citrome (2018), the American Academy of Neurology
recently updated their TD treatment guidelines, and based on available evidence an A
rating, which corresponds to established efficacy was awarded to two vesicular
monoamine transporter-2 (VMAT2) inhibitors. Fortunately for patients suffering from
TD, such as patients with schizophrenia unable to discontinue or augment their
antipsychotic regimen, Valbenazine and Deutetrabenazine were both approved in 2017
for the treatment of TD by the United States Food and Drug Administration (Ward &
Citrome, 2018). As studies are being conducted on the efficacy and safety of these
VMAT2 inhibitors in treating TD among patients taking antipsychotics for various mood
disorders, such as bipolar disorder, major depressive disorder, schizophrenia, and other
psychiatric disorders, this specific DNP project focuses on patients diagnosed with
schizophrenia. Research exists indicating that the impact of TD on health-related quality
of life (HRQoL) for patients with bipolar disorder, major depressive disorder, and
schizophrenia indicates that patients with schizophrenia and TD scored significantly
lower on both mental and physical health-related quality of life measures (McEvoy et al.,
2019).
Background
Tardive dyskinesia is classified as a hyperkinetic movement disorder that can be
irreversible with localized or widespread involuntary movements (McEvoy et al., 2019).
TD was first documented in 1957 after orofacial movements were noted with the
3

antipsychotic chlorpromazine and persisted after discontinuation or withdrawal (Caroff et
al., 2018). Despite the available literature on the management of TD since TD was
initially documented, guidelines on the management of TD remain inconsistent, difficult
to understand, and appear geared towards the expert
care provider to decipher the intricacies (Vasan & Padhy, 2021). Some studies
have shown improvement when the antipsychotic is decreased or discontinued, yet others
have not. Some studies suggested using more potent antipsychotics, which is not
supported by the American Academy of Neurology (2013), as neuroleptic agents cause
TD and can mask symptoms rather than treat the symptoms. As noted by Carroll and
Irwin (2019), “among patients with TD, healthcare utilization increased significantly in
the 12 months after diagnosis compared with the 12 months before diagnosis, which
included an overall increase in inpatient admissions, emergency room visits, and
outpatient visits” (p. 815).
The approval of the VMAT2 inhibitors for the treatment of TD offers a solution to
a problem previously riddled with inconsistent, unsatisfactory answers. For a patient
diagnosed with schizophrenia, it is not clinically feasible to discontinue his antipsychotic
and if the patient’s psychotic symptoms are stable, switching antipsychotics generally
would not be in the best interest of the patient, especially if the patient is tolerating his
current medication regimen. As noted by Ricciardi et al. (2019) “the strongest current
evidence for TD treatment is the use of the VMAT2 inhibitors, deutetrabenazine, and
valbenazine” (p. 396). Available literature indicates that the VMAT2 inhibitors are
effective for the treatment of TD with more favorable side effects; however, VMAT2
inhibitors are not widely available, they are expensive, they are not formulary, and there
4

is minimal long-term safety data available about the use of these inhibitors. If VMAT2
inhibitors are truly effective at treating TD, additional studies with data quantifying the
effectiveness would be beneficial to the body of literature to help establish evidencebased guidelines for the management of TD that can be easily followed by primary care
providers as well as psychiatric healthcare providers.
Significance
The symptoms of TD can have a significant effect on a patient’s HRQoL as even
subtle involuntary facial movements can have a significantly negative social and
emotional correlation (McEvoy et al., 2019). McEvoy et al. (2019) estimated that the
prevalence of TD is expected to increase due to the increased incidence of early-onset
schizophrenia. Studies have shown that individuals with schizophrenia have higher
mortality rates (McEvoy et al., 2019). For patients with schizophrenia, antipsychotics
remain the best option for treating psychotic symptoms despite awareness that all FGAs
and SGAs have the potential to cause TD (Jackson et al., 2021). Patients with TD can
display impairments in several body systems, impacting their ability to carry out
activities of daily living (ADLs). TD can affect gait and stability, speech, fine motor
skills, and range of motion, creating challenges with psychosocial functioning (Strassnig
et al., 2018). With so much focus on involuntary movements caused by TD, it is easy to
forget that TD goes beyond involuntary movements and often affects patients socially,
biologically, and psychologically. As noted by Jackson et al. (2021) “TD can have a
profound negative impact on patient's day to day functioning and may lead to negative
physical, cognitive, and psychosocial outcomes” (p. 1590). To assess the overall impact
of TD on an individual, the social, physical, vocational, psychological, and psychiatric
5

domains must be assessed (Jackson et al., 2021) at each visit. Now that the FDA has
approved 2 VMAT2 inhibitors for the treatment of TD, patients with schizophrenia do
not have to alter their antipsychotic regimen to obtain relief from the debilitating
symptoms of TD. Adding a VMAT2 inhibitor to the medication regimen has shown
efficacy in modulating the symptoms of TD, however according to Stahl (2018) this
inhibition is reversible and can be affected by changes in psychosis, mood, and other
factors that also affect dopamine levels, therefore clinicians must be skilled in the ability
to balance these factors when initiating VMAT2 inhibitors to ensure optimal patient
outcomes. Effectively assessing the impact of VMAT2 inhibitors on TD symptoms
through statistically significant improvements in assessment tools such as the Abnormal
Involuntary Movement Scale (AIMS) can help generate best practice recommendations
for TD treatment for healthcare providers.
Significance to Healthcare and Advanced Nursing Practice
The DNP-prepared advanced practice practitioner’s role entails the ability to
discern nuances in research to translate those findings into ways to improve patient care
and clinical practice (Zaccagnini & Pechacek, 2021). The skill of translating research into
practice requires the ability to address a complex clinical problem, identify evidencebased interventions to address the problem, and incorporative leadership skills during the
implementation and evaluation of the outcomes with the overall goal of using new
evidence obtained to improve health outcomes, patient outcomes, and clinical processes
(Zaccagnini & Pechacek, 2021). Antipsychotics are a necessary component of
schizophrenia treatment; however, prolonged use increases an individual’s risk for
extrapyramidal side effects (EPS) such as tardive dyskinesia (Othman et al., 2013). The
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involuntary movements associated with tardive dyskinesia (TD) can affect a patient’s
mouth, lips, tongue, jaws, eyes, upper extremities, lower extremities, upper trunk, or any
muscle in the body, with the likelihood of TD increasing the longer a patient takes
antipsychotics (Othman et al., 2013). The physical disabilities, as well as the social and
psychological implications of TD, can affect a patient’s quality of life (QOL). According
to Othman et al. (2013), QOL is an important health outcome measure that includes life
satisfaction, social functioning, activities of daily living, and physical health. QOL has
been utilized as an important measure of how well patients with schizophrenia can
function and according to Othman et al. (2013), the severity of TD is negatively
associated with quality of life which is consistent with prior studies indicating patients
with schizophrenia have a poor quality of life and TD is one of the contributing factors to
poor quality of life. As a healthcare provider and DNP-prepared advanced practice
practitioner with a goal to improve patient outcomes, these findings outline the
importance of recognizing and treating TD as efficiently as possible to improve the
quality of life for patients.
Problem Statement
Tardive dyskinesia (TD) can have a major impact on multiple functional domains.
The physical impact can impair communication by affecting swallowing, eating, gait,
posture, and ADLs like self-care (Jackson et al., 2021). The physical effects that patients
experience from TD can then affect their social relationships and affect them emotionally
and psychologically, eventually affecting their quality of life (Othman et al., 2013).
Jackson et al. (2021) note that “many patients and caregivers describe emotional and
social impacts of TD as the most debilitating features of this disease” (p. 1593). Patients
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describe unwanted attention from people staring at them as a culprit for feelings of selfconsciousness and embarrassment, which can also worsen underlying psychiatric
symptoms for patients already being treated for a mental health disorder. Some patients
can become depressed and isolated, leading to further declines in quality of life (Jackson
et al., 2021).
Available Knowledge
Current guidelines recommend the prevention of TD as the most important
concern in clinical practice. Healthcare providers are cautioned to follow best practice
guidelines when prescribing antipsychotics, which includes limiting prescription to
specific indications, prescribing the minimal effective dose, and minimizing the duration
of therapy when possible (Ricciardi et al., 2019). According to Correll et al. (2017; as
cited in Citrome, 2018), there are many different risk factors for TD such as older age,
antipsychotic exposure, female sex, African American ethnicity, prior mood disorder,
cognitive disorder, history of alcohol abuse, diabetes, being HIV positive, use of lithium
or antiparkinsonian agents, and use of FGAs. Education should be provided to patients
about modifiable risk factors to prevent TD. Avoiding antipsychotics and other dopamine
receptor blocking agents (DRBAs) is not possible in the management of schizophrenia as
antipsychotics are the only foundational treatment currently available for schizophrenia
(Citrome, 2018).
Before the FDA approval of VMAT2 inhibitors for the treatment of TD, few
concrete treatment options were available for TD. The most common management
strategy would include switching a patient from an FGA to an SGA while discontinuing
any anticholinergic medications the patient was currently taking (Citrome, 2018). If no
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improvement was noted in the TD, the patient would be switched to an alternate SGA,
then switched to Clozapine if there was still no improvement in TD symptoms (Citrome,
2018). Suppression therapy was an additional consideration for severe, potentially lifethreatening cases of TD, as was the case when TD interfered with breathing due to
diaphragm muscle involvement. Suppression therapy entailed masking the TD by adding
a potent first-generation antipsychotic medication (Citrome, 2018). In 2013, the
American Academy of Neurology (AAN) introduced guidelines stating that there was
insufficient data to support stopping the medication associated with TD to suppress
symptoms, as well as the strategy of switching from an FGA to an SGA (AAN, 2013).
The AAN also noted there was insufficient evidence to support or refute treatment of TD
with vitamin E, buspirone, electroconvulsive therapy, reserpine, and deep brain
stimulation, along with other strategies that have been posited throughout the years.
Needs Assessment
Attention to this issue at the local level was noted while working as a PMHNPDNP student in a community-based outpatient psychiatric care clinic in central
Mississippi. This healthcare facility provides comprehensive mental and physical health
services, ranging from psychiatry to internal medicine. Several patients with the
diagnosis of schizophrenia were noted with symptoms consistent with TD and required a
change in their medication regimen. Some patients were often prescribed alternate
antipsychotics, while others were noted on VMAT2 inhibitors. Some patients on VMAT2
inhibitors often were unable to tolerate one VMAT2 inhibitor and were subsequently
switched to another VMAT2 inhibitor to control TD symptoms. I wondered how much of
a change in the patients’ TD symptoms could be expected from adding the VMAT2
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inhibitors to their medication regimen, as opposed to simply switching their antipsychotic
medication. American Psychiatric Association (APA, 2013) guidelines recommend TD
monitoring every 6 months for patients treated with FGAs and every 12 months for
patients on SGAs. For patients who are at high risk for TD, more frequent evaluations are
indicated using a rating scale such as the AIMS scale to gauge improvements in
involuntary movements associated with TD. The psychiatrist making the changes to the
medication regimens had the knowledge to do so, which led me to also wonder if there
were any guidelines available for treating TD with VMAT2 inhibitors in schizophrenic
patients for other healthcare disciplines to reference in clinical practice. The FDA
approved two VMAT2 inhibitors for the treatment of TD in 2017, valbenazine and
deutetrabenazine. Given the emergence of these two drugs, the development of a
treatment algorithm for TD management with VMAT2 inhibitors in patients with
Schizophrenia is merited (Scorr &Factor, 2018) to guide collaboration across the
disciples of psychiatry, neurology, and primary care. As a DNP student, implementing an
evidence-based DNP project will add to the body of knowledge needed for the
development of a TD treatment algorithm. I developed a data collection tool that would
be utilized for this retrospective DNP project and discussed the findings with the medical
director and approval was obtained to determine if the addition of a VMAT2 inhibitor
compared to stopping, decreasing, or changing antipsychotics significantly decreases
tardive dyskinesia symptoms after 90 days of initiation in schizophrenic patients with TD
due to antipsychotic medication use.
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PICOT
Among patients diagnosed with schizophrenia and started on antipsychotic
medications, does the addition of a VMAT2 inhibitor, compared to stopping/decreasing
or changing antipsychotics significantly decrease tardive dyskinesia symptoms after 90
days?
Purpose and Objectives
The purpose of this doctoral DNP project is to determine if VMAT2 inhibitors are
more effective at treating tardive dyskinesia than previous alternatives in a real-world
experience. The objective is to identify a statistically significant decrease in tardive
dyskinesia symptoms for patients on VMAT2 inhibitors utilizing the AIMs to establish a
clinically significant reduction in TD severity (Stacy et al., 2019). The aim is to increase
the knowledge base of the healthcare profession on the use of VMAT2 inhibitors to treat
TD and to add to the body of knowledge required to eventually increase access and
availability of VMAT2 inhibitors to all patients, decrease costs of VMAT2 inhibitors to
help establish them as available options on healthcare formularies and to establish
evidence-based guidelines for the development of a treatment algorithm/protocol for TD
management with VMAT2 inhibitors in patients with Schizophrenia.
Concepts
Abnormal Involuntary Movement Scale (AIMS)
The abnormal involuntary movement scale (AIMS) is a screening tool used to
monitor symptoms of abnormal movement related to antipsychotic medication use
(Stacey et al., 2019).
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First Generation Antipsychotics (FGAs)
The earliest effective treatment for schizophrenia and other psychotic illnesses is
also called conventional antipsychotics, classical antipsychotics, or typical antipsychotics
(Stahl, 2018).
Health-Related Quality of Life (HRQoL)
Health-related quality of life (HRQOL) is an individual’s or a group’s perceived
physical and mental health over time (Centers for Disease Control and Prevention [CDC],
2021).
Neuroleptics
Antipsychotic drugs used to treat psychiatric disorders (Carroll & Irwin, 2019)
Quality of Life (QOL)
Similar to Health-Related Quality of Life.
Second Generation Antipsychotic (SGAs)
Second-generation antipsychotics (SGAs), also known as atypical antipsychotics,
generally have a lower risk of extrapyramidal side effects and tardive dyskinesia
compared with first-generation antipsychotics (Stahl, 2019).
Tardive Dyskinesia (TD)
A hyperkinetic movement disorder is defined by abnormal involuntary
movements that occur most often in the orofacial area but can occur in the neck, trunk,
upper and lower extremities, and any muscles (Jackson et al., 2021).
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
The vesicular monoamine transporter type 2 (VMAT2) inhibitors are agents that
cause a depletion of neuroactive peptides such as dopamine in nerve terminals and are
12

used to treat chorea due to neurodegenerative diseases, or dyskinesias due to neuroleptic
medications (Stahl, 2018).
Theoretical Framework
This DNP project will utilize a portion of The Theory of Unpleasant Symptoms as
a foundational guide. The Theory of Unpleasant Symptoms, which was developed in
1995 presents three main elements: the symptoms that the patient is experiencing; the
factors that influence those symptoms, and the consequences of that experience (Gomes
et al., 2019). Experienced symptoms are the central focus of the model, described as
indicators of change in the health status of the individual, which often occurs multiple
times and simultaneously. The theory outlines four dimensions: intensity, time, suffering,
and quality; as well as three categories of these dimensions which are the physiological,
psychological, and situational factors that relate to each other beyond their individual
relationships with the symptoms (Gomes et al., 2019). The final component of the Theory
is the consequence that reflects the functional and cognitive responses given to the
experience of the symptoms (Gomes et al., 2019). As noted by Gomes et al. (2019), the
Theory of Unpleasant Symptoms is very useful in research “because the theory provides
the identification of the dimensions of the symptoms and their relationships, which can be
used as a starting point for the development of clinical instruments and research, since it
is sufficiently precise in its theoretical framework” (p. 7).
The Knowledge to Action Framework will also be utilized as a conceptual
framework for the implementation of this DNP project. According to Field et al. (2014),
conceptual frameworks are broad and provide a frame of reference for organizing
thinking and provide a guide for action and interpretation. The Knowledge to Action
13

Framework (KTA Framework), “is a conceptual framework intended to help those
concerned with knowledge translation deliver sustainable, evidence-based interventions”
(Field et al., p. 2). The KTA Framework was developed by Dr. Ian Graham and
colleagues in Canada in the 2000s as a response to the multitude of terms used to describe
the process of moving knowledge into action (Field et al., 2014). The KTA Model
Framework is composed of two components, Knowledge Creation and the Action Cycle
with each component having several phases that overlap. The Action phases can be
conducted simultaneously, and knowledge phases impact the action phase (Field et al.,
2014). The Action Cycle describes the process representing the activities needed for
knowledge to be applied to practice, whereas knowledge is adapted to the local content
allowing for barriers and facilitators of its use to be assessed (Field et al., 2014). For this
DNP project, application of the “Action” cycle will entail the activities during the
implementation portion of this DNP project as I collect data on patients via retrospective
chart reviews utilizing the data collection tool. The results obtained will be utilized to
decipher the specific knowledge obtained from the DNP project, which will then be
utilized to help establish if the results will be disseminated as “Knowledge into Action”
into the healthcare environment.
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Figure 1. Knowledge to Action Cycle.
(Graham et al., 2006, pp. 24).

Synthesis of Evidence
A literature search was conducted on the following databases: CINAHL,
MEDLINE, PsychINFO, PubMed, Google Scholar, Cochrane Database, and Science
Direct. Key terms used in the review of literature were: tardive dyskinesia, schizophrenia,
evidence-based treatment, VMAT2 inhibitors, screening for tardive dyskinesia, abnormal
involuntary movement scale, Secondary terms were “social function for schizophrenia”,
“antipsychotic screening for tardive dyskinesia,” “tardive dyskinesia management and
schizophrenia,” “treatment of tardive dyskinesia,” “VMAT2 inhibitors and
schizophrenia,” “abnormal involuntary movement scale,” “health-related quality of life,”
“knowledge to action framework,” “frameworks.” Filters included full-text articles
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written between the years 2012 to 2021. The search yielded over 900 articles. These
articles were narrowed down based on whether they included the main criteria which
were information about 5 specific topics: tardive dyskinesia, schizophrenia,
antipsychotics, the AIMS, and VMAT2 inhibitors. Articles were excluded that focused on
“movement disorders, as opposed to specifically on tardive dyskinesia. From the articles
reviewed, 30 were selected for a critical appraisal for inclusion in the DNP project.
Prevention of Tardive Dyskinesia
Tardive dyskinesia is a hyperkinetic disorder that affects patients’ orofacial
muscles, neck muscles, neck and trunk muscles as well as upper and lower extremity
muscles (Jackson et al., 2021). Consensus in the literature is that prevention of TD is the
most important consideration in the management of TD, therefore clinicians should be
cautious to ensure they are following best practice guidelines when prescribing
antipsychotics, utilizing minimal effective dosages, and minimizing the duration of
therapy when possible (Ricciardi, 2019). As noted by Strassnig et al. (2018), there are
patients prescribed antipsychotics who have no diagnosis of a condition that would
require antipsychotics. Antipsychotics are also being prescribed off-label to allay
symptoms unrelated to psychosis. Healthcare providers should identify alternative
treatment options for these patients when considering the risk/benefit analysis. Citrome
(2018) also notes that ideally, it is best to prevent TD by identifying modifiable risk
factors and working with patients to eliminate those risk factors such as alcohol and
substance abuse.
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Tardive Dyskinesia Causes Decline in Quality of Life
TD can have a significant negative impact on a patient's daily functioning, leading
to negative physical, cognitive, and psychosocial outcomes. Even mild physical
impairments can cause anxiety and problems with activities of daily living (Jackson et al.,
2021). Healthcare professionals must assess patients with TD for impairments in social
functioning, physical functioning, vocational functioning (job duties, employment),
psychological functioning, as well as for worsening of their psychiatric disorders, as these
impairments can worsen due to insufficient control or relapse (Jackson et al., 2021). As
noted by McEvoy et al. (2019), patients with TD and schizophrenia had the lowest scores
on all health-related quality of life indicators indicating that TD has a major impact on
the physical health burden for patients already experiencing the burden of mental illness.
According to Caroff et al. (2018) “studies have shown correlations between impaired
cognition, poor response to treatment, greater risk of relapse, longer hospital stays, lower
quality of life and functioning, a progressive course, and increased mortality” (p. 3). As
noted by Othman et al. (2013), quality of life is an important health outcome measure that
includes life satisfaction, social functioning, activities of daily living, and physical health,
and is an important indicator of how well patients with schizophrenia are functioning.
Otthman et al. (2013) found that the severity of TD was negatively correlated with
quality of life.
FGAs and SGAs May Have Similar TD Risk
The literature shows that TD can occur during or after stopping treatment with a
dopamine receptor antagonist or partial agonist, which includes both FGAs and SGAs
(Jackson et al., 2021). The literature also indicates that although SGAs were identified as
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having a lower likelihood of causing TD, the research on SGA’s is inconsistent as there
are as many studies to refute the efficacy as there are to corroborate the claims. Ward and
Citrome (2018), note that more studies will be necessary to determine the impact of
atypical antipsychotics/SGAs on TD risk, citing a real-world prospective DNP project
which noted that the adjusted TD incidence rate for patients on SGAs alone versus FGAs
alone was only 0.68 with a 95% confidence interval of 0.29 to 1.64 which suggests that
there may be little to no difference between the two classes of antipsychotics as it relates
to TD risk.
VMAT2 Inhibitors are Effective Treatments for Tardive Dyskinesia
The use of deutetrabenazine and valbenazine has been proven to be effective in
the treatment of TD, although further studies are needed to solidify the safety and
efficacy of these drugs due to their new nature (Ricciardi, 2019). Caroff, Aggarwal, and
Yonan (2018) documented the clinical effectiveness of valbenazine in the treatment of
TD in larger, more rigorously designed studies. Stahl (2018), also noted the effectiveness
of VMAT2 inhibitors in treating TD, but also noted that this inhibition is reversible and
the degree of VMAT2 inhibition needed for a specific patient depends on several factors
and can be affected by mood as well as psychosis status (Stahl, 2018). Ward and Citrome
(2018) note that Level A evidence for efficacy exists for VMAT2 inhibitors, and there are
no additional FDA-approved medications for the treatment of TD.
Summary of Evidence
The use of deutetrabenazine and valbenazine has been proven to be effective in
the treatment of TD, although further studies are needed to solidify the safety and
efficacy of these drugs due to their new nature (Ricciardi, 2019). Caroff et al. (2018)
18

documented the clinical effectiveness of valbenazine in the treatment of TD in larger,
more rigorously designed studies. Stahl (2018), also noted the effectiveness of VMAT2
inhibitors in treating TD, but also noted that this inhibition is reversible and the degree of
VMAT2 inhibition needed for a specific patient depends on several factors and can be
affected by mood as well as psychosis status (Stahl, 2018). Ward and Citrome (2018)
note that Level A evidence for efficacy exists for VMAT2 inhibitors, and there are no
additional FDA-approved medications for the treatment of TD.
DNP Essentials
At the culmination of this DNP project, the DNP essentials have been met. The
DNP Essentials outlined in this DNP project establish mastery of the advanced practice
nurse practitioner discipline. Essential I: Scientific Underpinnings for Practice (American
Association of Colleges of Nursing (AACN), 2006) was fulfilled by integrating the
science of nursing using analytical approaches to evaluate current processes for
implementing guidelines for the management of tardive dyskinesia with VMAT2
inhibitors in patients with schizophrenia. Knowledge obtained was analyzed and
organized to develop an algorithm for the management of tardive dyskinesia for patients
with schizophrenia. Essential II: Organizational and Systems Leadership for Quality
Improvement and Systems Thinking (AACN, 2006), was met by utilizing advanced
communication processes throughout the implementation of this DNP project to gain
collaborative knowledge on the subject matter from doctors, nurse practitioners, as well
as executive pharmaceutical representatives to improve patient safety and analyze the
cost-effectiveness of VMAT2 inhibitor use for the treatment of tardive dyskinesia.
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Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice
(AACN, 2006) was met by applying relevant findings to develop a treatment protocol for
the management of tardive dyskinesia with VMAT2 inhibitors in patients with
schizophrenia. Essential VI: Interprofessional Collaboration for Improving Patient and
Population Health Outcomes (AACN, 2006) was met by using leadership skills with
interprofessional collaboration to create change in the process for managing tardive
dyskinesia (TD). Essential VII: Clinical Prevention and Population Health for Improving
the Nation’s Health (AACN, 2006), was met using statistical measures to analyze the
DNP project population. Essential VII was also met by statistical measures to synthesize
concepts from the population to evaluate data results and provider interventions to
identify outcomes. Essential VIII: Advanced Nursing Practice (AACN, 2006) was met
through the comprehensive assessment of management practices of providers in a rural
health clinic. Advanced levels of clinical judgment, systems thinking and evaluating
evidence-based care to improve patient outcomes were demonstrated throughout the
implementation of the DNP project. An algorithm for the management of TD with
VMAT2 inhibitors in patients with schizophrenia was developed to educate healthcare
professionals to improve patient outcomes and minimize interruptions in patients’ stable
antipsychotic regimens.
Summary
Tardive dyskinesia is a treatable side-effect of antipsychotic medications. The
increasing use of antipsychotic drugs and the implications this increased use has for
tardive dyskinesia monitoring raises concerns. As antipsychotics are being used to treat
more than just schizophrenia, health-related quality of life has the potential to decrease.
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The emergence of VMAT2 inhibitors provides the opportunity for patients on
antipsychotics to remain on their medication regimens when tardive dyskinesia symptoms
emerge; however, healthcare providers in areas unrelated to mental health need readily
available resources to help them gain familiarity with VMAT2 inhibitors and how to
initiate and manage them. The literature indicates VMAT2 inhibitors are effective at
controlling TD symptoms. Several DNP essentials will be utilized to implement a DNP
project to gauge how efficiently the VMAT2 inhibitors are able to control TD symptoms
in patients with schizophrenia.
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CHAPTER II - METHODS
Setting
The setting for this DNP project with be mainly in a rural healthcare clinic that
provides holistic care to patients. The clinic provides general medicine, psychiatric
services as well as professional counseling and psychosomatic care to the patient
population served. The clinic utilizes a comprehensive approach to mental wellness that
meets patients where they are to get them where they need to be. This is a privately
owned clinic located in an urban Metropolitan area. The clinic accepts all types of health
insurance; however, a majority of the patients utilize Medicare and Medicaid. Uninsured
patients are also accepted at this facility and are billed for services based on a self-pay
system. Demographic data for the location of this clinic indicates that the population
base consists of 54.77% females and 45.23% males. The racial make-up of the population
served by this rural health clinic consists of 53% Caucasians, 39% African American, 5%
Asian, and 3% other races.
This clinic consists of two providers that can prescribe medications: one
psychiatrist (Doctor of Medicine), and one dually certified Family Nurse
Practitioner/Psychiatric Mental Health Nurse Practitioner, as well as rotating Nurse
Practitioner students and rotating Physician Assistant students. The psychiatrist and nurse
practitioner at this facility also have prescribing privileges at four different clinic
locations as well as three group homes. Data from the medical records will be collected
from all these locations. This practice was selected as the source for gathering
information because the principal investigator (PI) spent clinical time in these clinics and
had the opportunity to interact with patients taking psychotropic medications that caused
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tardive dyskinesia and noted a significant number of these patients had a diagnosis of
schizophrenia. A letter of support from the clinic director was obtained before
implementing the DNP project.
Population
The population for this DNP project includes a convenience sample of mental
health patients between the ages of 20 to 75 years of age that have been diagnosed with
schizophrenia and started on antipsychotic medications and subsequently initiated on a
VMAT2 inhibitor for the presence of tardive dyskinesia symptoms. This DNP project
entails a retrospective review of medical records and progress notes completed by
prescribing providers (MD, NP, PA). The 10th version of the International Classification
of Disease (ICD-10) was used to identify diagnosis codes for inclusion in this DNP
project. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-V) was also utilized to identify diagnosis codes for inclusion in this DNP project.
All psychiatric diagnoses identified by DSM-V to fall under the schizophrenia spectrum
and other psychotic disorders were reviewed for inclusion in this DNP project. The DSMV diagnoses chosen for inclusion in this DNP project are identified within ICD-10 codes
F20 through F29, specifically F20.9 (Schizophrenia), F20.81(Schizophreniform disorder),
F21 (schizotypal disorder), F22 (Delusional Disorder), F25.0 (schizoaffective disorder,
bipolar type, and F25.1(schizoaffective disorder, depressive type). Additional ICD-10
codes pertinent for inclusion in this project include G24.01 (Drug-Induced Subacute
Dyskinesia), and G24.4 (Orofacial Dyskinesia).
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Design
This DNP project is a descriptive study. The DNP project will include a
retrospective chart review of medical records and progress notes entered by prescribers to
determine if the use of VMAT2 inhibitors, compared to decreasing, stopping, or changing
antipsychotics, significantly decreases tardive dyskinesia symptoms after 90 days. Data
collected from the chart reviews were recorded on the data collection tool developed
specifically for this DNP project. The data collection tool allowed for patients to be
assigned a random identification number with no identifying information on the form.
Data collected was then transferred to an Excel spreadsheet and SPSS was utilized to
analyze the data and make interpretations for the DNP project results.
Procedures
After obtaining USM IRB approval (protocol # 21-307), a retrospective chart
review will be conducted to identify patients that meet inclusion criteria for this DNP
project. The medical records of those patients will be reviewed to determine the
prescribing providers' course of action after the diagnosis of tardive dyskinesia has been
identified or documented. Specifically, the medical records will be reviewed to identify
those patients initiated on VMAT2 inhibitors versus those patients in whom the
prescribing provider chose to either decrease, stop, or change the antipsychotic deemed
responsible for the tardive dyskinesia symptoms. The medical records will also be
reviewed to identify the AIMS score utilized to document the baseline assessment, as
well as the AIMS scores documented to assess TD symptom improvement. The data
extractor is a part-time/PRN prescriber and family nurse practitioner (FNP) at the rural
healthcare clinic.
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Progress notes and medical records will be accessed by the data abstractor.
Records from the timeframe of January 01, 2020, through the present day, will be
abstracted for inclusion criteria which include males and females between the ages of 20
to 75 years with a diagnosis identified within the schizophrenia spectrum and other
psychotic disorders which includes “schizophrenia, schizotypal disorder, and other
psychotic disorders, which are identified based on abnormalities in one or more of the
five domains of delusions, hallucinations, disorganized thinking or speech, grossly
disorganized or abnormal motor behavior, and negative symptoms” (APA, 2013, p. 87).
For the patients that meet inclusion criteria, I will identify those that were initiated
on VMAT2 inhibitors, those whose antipsychotic was stopped, and those whose
antipsychotic was changed to a different antipsychotic. I will then compare the initial
AIMS score from when Tardive Dyskinesia (TD) was first diagnosed with the AIMS
scores at 30 days, 60 days, and 90 days follow-up to determine what impact each had on
the AIMS scores. The goal is to determine if VMAT2 inhibitors have a more profound
effect on the AIMS score. The long-term goal is to help add to the literature to establish
VMAT2 inhibitors as a credible treatment for patients with tardive dyskinesia in hopes of
making these medications more widely available, formulary, and establishing them as 1st
line treatment for TD.
Data Collection
A retrospective record review will be done by the principal investigator (PI) to
collect data regarding Tardive Dyskinesia Symptoms. A data collection form has been
developed for utilization in this DNP project. No identifying information will be on the
data collection form. The data collected on the data collection tool will include a few
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basic demographics, whether there is a diagnosis of schizophrenia, and if the patient was
started on antipsychotics. The specific data collected will include age, sex, race,
Schizophrenia diagnosis, whether the patient was started on an antipsychotic, whether the
patient has a documented diagnosis of tardive dyskinesia, the date TD was first
documented, initial AIMS score, prescribing provider’s intervention (whether initiated on
a VMAT2 inhibitor, or whether the antipsychotic was stopped, changed, or decreased),
and the AIMS score at 30 days, 60 days, and 90 days post provider intervention.
Information from the data collection tool will then be transferred to an excel spreadsheet.
Data will then be analyzed and reported in a de-identified, aggregate form.
Protection of Human Subjects
Participants’ anonymity and confidentiality will be maintained. IRB approval for
this DNP project was requested through the University of Southern Mississippi’s
Institutional Review Board (IRB) and approval was granted through Protocol Number
21-307. To protect the confidentiality, data will be recorded on a password-protected
spreadsheet on an encrypted file, using only a unique study number. Data will be
analyzed and reported in a de-identified, aggregate form. DNP project records will be
stored on the investigator’s identity authenticated, secure firewall-protected, personal
computer. Every effort will be made to maintain the confidentiality of DNP project
records. Information collected during the DNP project will be identified by a unique DNP
project number. Information from the medical record will be recorded on a passwordprotected spreadsheet on an encrypted file. Data were analyzed and reported in a deidentified, aggregate form. Investigational records from this DNP project will be
maintained in a confidential manner. Consistent with IRB retention requirements, the
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DNP project records will be maintained for six years after completion of the DNP
project. Thereafter, paper and electronic records will be destroyed or erased using data
overwriting software per USM policy and confidential methods. Subsequent analyzed
aggregate data will be maintained to enable retrieval if requested during consideration for
publication. The DNP project is no greater than minimal risk and will have no direct
impact on patients’ rights, welfare, or clinical care. Identified measures were
implemented to minimize the risk of a breach of confidentiality during record review and
data collection.
Ethical Considerations
According to Chism (2019), the Belmont Report states that “if there is any
element of research in an activity, that activity should undergo review for the protection
of human subjects” (p. 111). The Belmont Report identifies three principles for human
subject research which include: respect for persons, beneficence, and justice. These
principles, discussed in further detail below are utilized to analyze and resolve ethical
concerns in healthcare issues related to human subjects.
Respect for Persons
Respect for persons, as noted by Chism (2019) involves maintaining an
individual’s capacity for autonomous choice, respecting the privacy of individuals,
protecting confidential information, obtaining consent for interventions, and helping
individuals make important decisions when asked. This DNP project is a retrospective
chart review. I am obtaining data from records in existence at the time of this submission.
The DNP project involves no prospectively collected data so there is no access to patients
or opportunity to seek informed consent. A waiver of consent will be sought from the
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USM IRB as recontacting these patients to obtain informed consent would be
impracticable and would hinder this researcher’s ability to conduct the study. Although
the principal investigator will know who the patients are initially while conducting chart
reviews of the medical records, anonymity will be maintained beyond this point via deidentification and the use of codes that cannot be used to identify the patients.
Beneficence
As noted by Chism (2019), the principle of beneficence entails the obligation to
act for the benefit of others. A general requirement for beneficence is knowing the values,
beliefs, and cultural practices of individuals to act in their best interest. This DNP project
consists of a retrospective chart review based on documented information already present
in the patients’ medical records and progress notes. There is no direct contact with these
patients and no opportunity to delineate their values, beliefs, or cultural practices unless
previously documented in the records. No harm will be inflicted on participants as this is
a retrospective chart review. The principle of beneficence is noted in this DNP project by
the long-term goals of the study. The long-term goal is to help add to the literature to
establish VMAT2 inhibitors as a credible treatment for patients with tardive dyskinesia in
hopes of making these medications more widely available, formulary, and establishing
them as 1st line treatment for TD. There are no direct benefits for the patients enrolled in
this DNP project. Rather, future patients requiring treatment for tardive dyskinesia may
benefit from knowledge gained from this DNP project.
Justice
The principle of justice entails treating people without prejudice and incorporates
the equitable distribution of benefits as well as burdens (Chism, 2019). The privacy of
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patients selected for this DNP project based on inclusion criteria will be maintained and
all data from the selected patients will be treated fairly and equally. Although the
sampling for this DNP project involves a convenience sample, selected patients will be
chosen based on meeting all inclusion criteria without prejudice.
Summary
The methods used to implement this DNP project followed the office of Research
Integrity guidelines ensuring risk to subjects was minimized and the data collected was
monitored to ensure the safety of the patients. Patient privacy and data confidentiality
were maintained by using a carefully designed plan that allowed for patients to be
assigned random identification numbers with no identifying information. Although this
was a retrospective review, ethical principles such as respect for persons, beneficence,
and justice were utilized in the data collection process. Ensuring proper procedures are
implemented during the data gathering process, improves the reliability of the results.
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CHAPTER III – RESULTS
The purpose of this DNP project was to determine if VMAT2 inhibitors are more
effective at treating tardive dyskinesia than previous alternatives in a real-world
experience. A retrospective chart review was performed on 70 records that were chosen
through a convenience sample of patients being treated by one physician and two nurse
practitioners. An exhaustive chart review was conducted on each record for DNP project
inclusion criteria. Each chart was reviewed to determine if the patient had the required
DSM-V Schizophrenia Spectrum and related disorders diagnosis, and if so, the earliest
date noted for when the patient was diagnosed was also identified. The date the patient
was started on an antipsychotic for schizophrenia was also identified, along with any
documentation of tardive dyskinesia symptoms, or suspected tardive dyskinesia
symptoms. If there was documentation of tardive dyskinesia (TD) present, the date the
patient’s tardive dyskinesia symptoms first started was noted. The intervention the
healthcare provider planned to implement was also identified and noted along with the
date the intervention was implemented. The charts were also reviewed to ensure that
AIMs scores were present.
Within the 70 charts reviewed, when patients were noted to show positive signs of
tardive dyskinesia that met treatment guidelines, there was no documentation of the
healthcare providers changing the patients’ antipsychotics, stopping their antipsychotics,
or decreasing their antipsychotics. The main intervention was the initiation of a VMAT2
inhibitor for the treatment of TD, therefore no records were identified for comparison
with the intervention of initiation of a VMAT2 inhibitor. The date the patient was started
on the VMAT2 inhibitor was identified along with the initial AIMs score when the
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intervention was implemented. AIMs scores were identified for the patients at four
weeks, eight weeks, and twelve weeks after the VMAT2 inhibitor was initiated, along
with the dates when these AIMs scores were obtained. The current VMAT2 inhibitor that
the patient was on was also noted at four, eight, and twelve weeks.
Fifteen (N=15) records were identified to meet inclusion criteria for the DNP
project. All records included in this DNP project are for patients between the ages of 25
to 65 on an approved VMAT2 inhibitor for at least 90 days, with a diagnosis within the
DSM-V Schizophrenia Spectrum and other Psychotic Disorders of either: (a)
schizophrenia (F20.9), (b) schizophreniform disorder (F20.81), (c) schizotypal disorder
(F21), (d) delusional disorder (F22), or (e) schizoaffective disorder (F25.0). The data
from the reviews was logged on the data collection tool created by the principal
investigator, and the data were analyzed using SPSS to conduct a Repeated Measures
Analysis of Variance (ANOVA) on the data. All of the patients that met inclusion criteria
were male (N=15; 100%). Over half of the patients were African American males (N= 8;
53.3%), 40% (N=6) were Caucasian, and 6.7% (N=1) were Asian. Forty percent of the
patients (N=6) were between the ages of 56-65, another 40% (N=6) were between the
ages of 46-55, an additional 13.3% (N=2) were between the ages of 36-45, and 6.7%
(N=1) were between the ages of 25-35.
Table 1 identifies the AIMS scale scores for each of the 15 patients as well as the
medication each was initiated on for the treatment of TD. Eighty percent (N=12) of the
patients have initiated on Ingrezza 40mg and 20% (N=3) of the patients were initiated on
Austedo 6mg BID. The AIMS scale scores ranged from 11 to 18 which is clearly
depicted in Figure 2. Table 1 however, provides more insight on the percentage of
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patients taking each medication with the corresponding AIMS scores, as 66.7% (N=2) of
the patients that were started on Austedo were noted to have an initial AIMS score of 14.
After 30 days of being on the VMAT2 inhibitors, these patients were generally titrated to
the next dose by this 30-day period as Ingrezza can be increased from 40mg to 80mg
after one week and Austedo is usually initiated at 6mg twice a day and titrated up by 6mg
weekly as tolerated by the patient to a maximum dose of 48 milligrams daily in equally
(24 mg BID) divided doses (Stahl, 2019). Two of the patients’ medications were
switched before they reached the 30-day period. One patient was initially started on
Austedo 6mg but was switched to Ingrezza secondary to either no improvement or
worsening symptoms. This information was unclear from the documentation in the
patient’s chart. The other patient was taken off Ingrezza 40mg secondary to a possible
allergic reaction however the patient was switched to Austedo 6mg without any problems
weeks later.
Table 1
Initial AIMs Test Score * Initial VMAT2 Inhibitor Initiated Crosstabulation
Medication@Initial
Ingrezza 40mg
N
Initial AIMs

Total

Austedo 6mg BID

%

N

%

Total
N

%

11

1

8.3%

0

0.0%

1

6.7%

12

2

16.7%

0

0.0%

2

13.3%

13

3

25.0%

0

0.0%

3

20.0%

14

1

8.3%

2

66.7%

3

20.0%

15

2

16.7%

0

0.0%

2

13.3%

16

2

16.7%

1

33.3%

3

20.0%

18

1

8.3%

0

0.0%

1

6.7%

12

100.0%

3

100.0%

15

100.0%
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Figure 2. Graph by Medication of AIMs Scores for all Patients when VMAT2 Inhibitor
Initiated
As noted in Table 2, the AIMS scale scores have decreased from a previous range
of 11-18 to 9-15 after the patients have been on the VMAT2 Inhibitors for at least 30
days. At this stage, the patients are on four different doses of VMAT2 inhibitors as 60 %
(N=9) of the patients have been titrated to the 80mg dose of Ingrezza, and 20% (N=3) are
still on Ingrezza 40mg. In addition to this 13.3% (N=2) have been titrated up to the 12
mg twice a day dosing of Austedo and there is one patient that is on Austedo 6mg twice a
day. As noted in Figure 3, of the nine patients on Ingrezza 80mg, 55.5% (N=5) of them
still have an AIMS score of 13 or above.
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Table 2
Initial AIMs Test Score * Medication After 30 Days Crosstabulation
Medication@30Days
Ingrezza 40mg

N

%

Ingrezza 80mg

N

Austedo 12mg BID

%

N

%

Austedo 6mg BID

N

%

Total

N

%

AIMSat30Da

9

0

0.0%

1

11.1%

0

0.0%

0

0.0%

1

6.7%

ys

11

1

33.3%

2

22.2%

0

0.0%

0

0.0%

3

20.0%

12

1

33.3%

1

11.1%

1

50.0%

0

0.0%

3

20.0%

13

0

0.0%

3

33.3%

0

0.0%

1 100.0%

4

26.7%

14

0

0.0%

1

11.1%

1

50.0%

0

0.0%

2

13.3%

15

1

33.3%

1

11.1%

0

0.0%

0

0.0%

2

13.3%

Total

3 100.0%

9 100.0%

2 100.0%

1 100.0%

15 100.0%

Figure 3. Graph of AIMS Scores for all Patients after 30 Days of VMAT2 Inhibitors Use
by Medication
After 60 days of VMAT2 Inhibitor use, 66.6% (N=10) of the patients had
documented AIMS scale scores of 10 to 11, as noted in Table 3 with a mean AIMS score
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of 11.13% at this time. During this timeframe, all patients had transitioned to Ingrezza
80mg or Austedo 12 mg with significant drops noted in some of the AIMS scale scores
for some patients, with one patient’s score being documented as 5 at this point and only
13.4% (N=2) of patients AIMS scores still above 12. Figure 4 again shows the AIMS
score counts by the medication the patient is currently taking after 8 weeks.
Table 3
Initial AIMs Test Score * Medication after 60 Days Crosstabulation
Medication@60Days
Ingrezza 80mg
N
AIMS@60Days

Total

Austedo 12mg BID

%

N

%

Total
N

%

5

1

8.3%

0

0.0%

1

6.7%

10

2

16.7%

0

0.0%

2

13.3%

11

4

33.3%

1

33.3%

5

33.3%

12

3

25.0%

2

66.7%

5

33.3%

13

1

8.3%

0

0.0%

1

6.7%

14

1

8.3%

0

0.0%

1

6.7%

12

100.0%

3

100.0%

15

100.0%

Figure 4. Graph of AIMS Score for All Patients after 60 Days of VMAT2 Inhibitors Use
by Medication.
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After 12 weeks, 80% (N=12) of the patients remained on Ingrezza 80 mg and
20% (N=3) remained on Austedo 12mg. The mean AIMS scale scores were 9.87% and,
the range of AIMS scale scores was from five to 13 as noted in Table 4 and Table 5.
Figure 4 shows the minimum and maximum point decrease in the AIMS total score for
all 15 patients that met inclusion criteria. According to these results three patients had a
two-point total decrease in their initial AIMS score, three patients had a three-point total
decrease in their initial score, one patient had a four-point decrease in his initial AIMS
score, four patients had a five-point total decrease in their AIMS scores, three patients
had a six-point total decrease in their initial AIMS score, and one patient had a sevenpoint total decrease in his AIMs scale score over the 12-week study.
Table 4
Initial AIMs Test Score * Medication After 90 Days Crosstabulation
Medication@90Days
Ingrezza 80mg
N
AIMS@90Days

Total

Austedo 12mg BID

%

N

%

Total
N

%

5

1

8.3%

0

0.0%

1

6.7%

9

1

8.3%

2

66.7%

3

20.0%

10

7

58.3%

0

0.0%

7

46.7%

11

2

16.7%

1

33.3%

3

20.0%

13

1

8.3%

0

0.0%

1

6.7%

12

100.0%

3

100.0%

15

100.0%
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Table 5
Descriptive Statistics for AIMS Scale Scores
N

Range

Minimum Maximum

Sum

Mean

Std. Deviation Variance

Initial AIMs

15

7

11

18

212

14.13

1.885

3.552

AIMSat30Days

15

6

9

15

188

12.53

1.642

2.695

AIMS@60Days

15

9

5

14

167

11.13

1.995

3.981

AIMS@90Days

15

8

5

13

148

9.87

1.685

2.838

Valid N

15

(listwise)

Figure 5. Bar Graph Showing Minimum to Maximum Point Decrease in the AIMS Total
Score.
Summary
The data from this DNP project shows that VMAT2 inhibitors are effective in
reducing tardive dyskinesia symptoms based on the statistically significant decrease in
AIMs scale score. The data also showed that healthcare providers in this study setting
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chose to implement VMAT2 inhibitors as opposed to stopping, changing, or decreasing
current antipsychotics in patients with schizophrenia. Although researcher was unable to
compare any patients on VMAT2 inhibitors with patients whose antipsychotic was
adjusted, the researcher was still able to compare AIMS scale scores over time for the
patients on VMAT2 inhibitors over a 90-day period. The study was able to determine
after analyzing the AIMS scale scores of the patients on VMAT2 inhibitors, that the
addition of a VMAT2 significantly decreased TD symptoms after 90 days.
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CHAPTER IV – DISCUSSION
The purpose of this DNP project was to identify a statistically significant decrease
in tardive dyskinesia symptoms for patients on VMAT2 inhibitors utilizing the AIMS
scale score to establish a clinically meaningful reduction in tardive dyskinesia severity
based on a 2-point decrease in AIMS total scores. The goals of the DNP project were to
determine if VMAT2 inhibitors had a more profound effect on the AIMS score than
stopping, changing, or decreasing antipsychotic medications, however, no patients were
found to meet these criteria during exhaustive charge reviews of the patient population.
Additional goals included increasing the knowledge base of the healthcare profession on
the use of VMAT2 inhibitors to treat tardive dyskinesia in patients with schizophrenia
and to develop a treatment algorithm for TD management with VMAT2 inhibitors in
patients with schizophrenia. The data from this DNP project shows that VMAT2
inhibitors are very effective in reducing tardive dyskinesia symptoms based on the AIMS
scale scores and a statistically significant 2-point decrease in AIMS total scores for all the
patients in this DNP project which is comparable to results obtained by previous studies
(Factor et al., 2017).
Interpretation
The effects of tardive dyskinesia can be physically, emotionally, and socially
limiting which can exacerbate any underlying mental health condition an individual
already has. VMAT2 inhibitors have been approved for the treatment of these symptoms
for patients who choose to receive treatment. Understanding the effects of VMAT2
inhibitors and how they affect various demographic populations in various settings will
help healthcare providers gain insight into best practices for caring for their patients.
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Although the initial direction of this DNP project was to gauge how much more effective
VMAT2 inhibitors are at augmenting TD symptoms than the other alternatives of
discontinuing, changing, or decreasing antipsychotic medications for patients with
schizophrenia, the available records did not identify patients that met these parameters.
Perhaps, the healthcare providers caring for the current patient population have already
adopted the recommendations of the AAN and APA to initiate “a reversible VMAT2
inhibitor as first-line treatment for moderate to severe or disabling tardive dyskinesia
secondary to antipsychotic therapy” (Keepers et al., 2020, p. 869). In patients with mild
TD, the APA notes that VMAT2 Inhibitors may be considered based on patient
preference, impairment, and impact on psychological functioning. A comparison
population would have added strength to the results; however, with the current patient
population of patients with schizophrenia who also have TD, augmenting the
antipsychotic therapy for these patients whose schizophrenia regimen is stable to correct
another issue could lead to further declines in quality of life for these patients. As noted
by McEvoy et al. (2019), TD is not a nuisance side effect, it impacts the well-being of
patients and can worsen the stigma associated with their underlying condition so
choosing treatment options for TD can be co-administered with the current antipsychotic
regimen is warranted.
Limitations
One of the main limitations of this DNP project is the AIMS scale scores. The
AIMS is designed to measure abnormal involuntary movements in patients on neuroleptic
medications. There are 12 items on the AIMS that the healthcare provider scores. The
total score from items one through seven is calculated to represent observed movements
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on a severity scale from zero, indicating none to four, indicating severe (Stacy et al.,
2019). The problem is the subjectivity of the AIMS scale as two different providers may
rate movements differently and what one provider deems is severe may be deemed as
mild to moderate to the next provider. Without knowing who scored the AIMS scales in
the retrospective DNP project, it is difficult to correct this limitation. The small sample
size may also be a limitation. A longer time frame and the ability to review records from
other facilities would have yielded a larger sample size, however, the data collected from
the current sample size showed a mean 4.27% decrease in AIMS scale scores overall in
the 12 weeks. Another limitation noted in this DNP project was the lack of completed
AIMS scale scores for patients that met all other inclusion criteria for this DNP project,
which excluded those patients from the DNP project as an AIMS scale was a major
requirement for this DNP project.
Implications for Practice
The implications for practice are to increase awareness for the evidence-based
practice guidelines recommending the use of VMAT2 inhibitors for the treatment of
tardive dyskinesia when treatment is indicated. Providers must become comfortable and
familiar with this drug class to ensure they offer these medications to patients when they
present with troubling symptoms of TD that can be managed. The results of this DNP
project will be shared with the key stakeholders of the facility with the recommendation
to improve documentation of the AIMS scale scores for patients on antipsychotics with
positive symptoms of TD to gauge the effectiveness of the VMAT2 inhibitors being
prescribed to determine what changes need to be implemented.
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Recommendations for Future Research
Future research ideas include studying the effect of tardive dyskinesia on
antipsychotic medication adherence. In addition, to this, Carroll (2019) noted that
healthcare utilization increased in the 12 months following TD diagnosis than in the 12
months prior to the diagnosis, additional research into the cause for this would be
beneficial in reducing healthcare expenditure and improving health-related quality of life
measures for these patients. Future research into antipsychotic medications that do not
cause tardive dyskinesia would also be beneficial by conducting additional research to try
to identify such medications.
Conclusion
This DNP project shows that VMAT2 inhibitors are effective at treating tardive
dyskinesia for patients with schizophrenia on antipsychotic medications and are unable to
discontinue these medications when TD symptoms become problematic. This DNP
project also determined that a statistically significant decrease in tardive dyskinesia
symptoms can be established based on the utilization of the AIMS scale for these same
patients. A clinically meaningful reduction in tardive dyskinesia severity was established
by a mean 4.27% decrease in AIMS scale scores overall in the 12 weeks. Schizophrenia
is a serious disorder that affects the daily functioning of those diagnosed with this
condition and requires lifelong management with antipsychotic medications. When these
necessary medications compound the physical, behavioral, and psychological impact
these patients are experiencing, this increases their risk for worsening psychiatric
symptoms. The availability of the VMAT2 inhibitors as an FDA-approved treatment
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option for TD is an opportunity for healthcare professionals to provide these patients with
an opportunity to improve their quality of life.
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APPENDIX A – Data Collection Tool
Identification Number ___________________
Demographic Information:
Age:
Sex
Race:
YES
Schizophrenia Diagnosis?
Started on Antipsychotic?
Documented Tardive Dyskinesia Symptoms?
Date First Documented
Initial AIMS Score:
PROVIDER'S INTERVENTION
(1) Initiated VMAT2 Inhibitor
Drug/Dose:

(2) Changed Antipsychotic
Previous Antipsychotic:
Changed to:

(3) Stopped Antipsychotic

AIMS Score 30 days later:
Med/Dose:
AIMS Score 60 days later:
Med/Dose:
AIMS Score 90 days later:
Med/Dose:
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NO

DATE

APPENDIX B – IRB Approval Letter

NOTICE OF INSTITUTIONAL REVIEW BOARD ACTION

The project below has been reviewed by The University of Southern Mississippi
Institutional Review Board in accordance with Federal Drug Administration regulations
(21 CFR 26, 111), Department of Health and Human Services regulations (45 CFR Part
46), and University Policy to ensure:
The risks to subjects are minimized and reasonable in relation to the anticipated
benefits.
The selection of subjects is equitable.
Informed consent is adequate and appropriately documented.
Where appropriate, the research plan makes adequate provisions for monitoring the
data collected to ensure the safety of the subjects.
Where appropriate, there are adequate provisions to protect the privacy of subjects and
to maintain the confidentiality of all data.
Appropriate additional safeguards have been included to protect vulnerable subjects.
Any unanticipated, serious, or continuing problems encountered involving risks to
subjects must be reported immediately. Problems should be reported to ORI via the
Incident submission on InfoEd IRB.
The period of approval is twelve months. An application for renewal must be submitted
for projects exceeding twelve months.
PROTOCOL NUMBER:
21-307
PROJECT TITLE:INITIAL SUBMISSION FOR VMAT2 INHIBITOR STUDY
SCHOOL/PROGRAM Leadership & Advanced Nursing
RESEARCHERS:PI: Ada Kelly Investigators: Kelly, Ada~Coleman, Carolyn~
IRB COMMITTEE ACTION: Approved
CATEGORY: Expedited Category
PERIOD OF APPROVAL:18-Nov-2021 to 17-Nov-2022

Donald Sacco, Ph.D.
Institutional Review Board Chairperson")
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APPENDIX C – Letter of Support

GORDON MEDICAL ARTS
Date: 6/19/2021
RE: Letter of Support for Ada Kelly, MSN, FNP-BC, MPH

Attn: Facility Nursing Research Council Application Process- DNP Student
To: Nursing Research Council Chair and Committee
This letter is in reference to Ada Kelly, MSN, FNP-BC, MPH who is applying for application and approval of her
Clinical Doctoral Project. The focus and title of her evidenced-based project is "In patients diagnosed with
Schizophrenia and started on antipsychotic medications, does the addition of a VMAT2 inhibitor compared to stopping
or changing antipsychotics decrease tardive dyskinesia symptoms after 90 days. " The site is in a community-based
outpatient clinic.
I have discussed this topic with Ada Kelly, MSN, FNP-BC, MPH and support and recommend the need for this
retrospective chart review of patients that have been on a VMAT2 inhibitor for at least 90 days. After data analysis,
I understand that Ada will present her findings to the Dr. Gordon and USM School of Leadership and Advanced
Nursing Practice.
I understand that following approval by the Nursing Research Council, she will seek approval from The University of
Southern Mississippi Institutional Review Board (IRB) for final approval of her Clinical Doctoral Project proposal.
At present, I understand that Ada Kelly, MSN, FNP-BC, MPH is a full-time DNP (Family Nurse Practitioner) student
in the Doctor of Nursing Practice Program at the University of Southern Mississippi, Hattiesburg campus.
I am the owner/director/CEO of Gordon Medical Arts Clinic. I am offering this letter of support of the doctoral
student Ada Kelly, MSN, FNP-BC, MPH, in her doctoral project as titled above and look forward to hearing her
findings.
I understand the planned dates are 30 days from when USM IRB approval is received. I understand that this
letter of support will be included in the University of Southern Mississippi Institutional Review Board (IRB)
application.
Her Chair contact information is Dr. Carolyn Coleman carolyn.coleman@usm.edu and cell 601 813 6218.
As Director/Chief of Staff at this proposed site, I would like to fully support Ada Kelly, MSN, FNP-BC, MPH to
achieve her academic endeavor in this clinical practice project. I look forward to hearing the results of this study
and the implications on clinical practice.
If there is any other information you should need, please do not hesitate to contact me.
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APPENDIX D - Algorithm/Protocol for TD Management with VMAT2 Inhibitors
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APPENDIX E – Review of Literature
Author/Year/Title

Design

Anderson, K. E., Stamler, D., Davis,
M. D., Factor, S. A., Hauser, R. A.,
Isojärvi, J., ... & Fernandez, H. H.
(2017)

Double-bling,
Placebocontrolled,
randomized
trial

Sample
Patients aged 18-80
years old with tardive
dyskinesia

Findings
From baseline to
week 12 the LS
mean AIMS score
improved.

Mean analysis
confirmed a
clinically
meaningful lower
TD risk with SGAs
vs FGAs which is
not driven b high
dose FGA
comparators
Valbenazine
appears to have
fewer side effects
and a more
favorable once-daily
dosing regimen for
TD treatment.

Deutetrabenazine for treatment of
involuntary movements in patients
with tardive dyskinesia (AIM-TD):
A double-blind, randomized,
placebo-controlled, phase 3
trial. The Lancet Psychiatry, 4(8),
595-604.

Carbon, M., Kane, J. M., Leucht,
S., & Correll, C. U. (2018).

MetaAnalysis

Tardive dyskinesia risk with
first‐and second‐generation
antipsychotics in comparative
randomized controlled trials: a
meta‐analysis. World
Psychiatry, 17(3), 330-340
Caroff, S. N., Aggarwal, S., &
Yonan, C. (2018)

All head to head
comparisons of specific
antipsychotics in any
oral or IM form to any
FGA without restriction
on age or gender of
participants

Systemic
Review

487 PubMed/Embase
search results/11 studies
met the review criteria

Treatment of tardive dyskinesia
with tetrabenazine or
valbenazine: a systematic
review. Journal of Comparative
Effectiveness Research, 7(2),
135-148.
Carroll, B., & Irwin, D. E.
(2019)

Retrospective
analysis

834 patients diagnosed
with TD for the first
time between January 1,
2008, and September 30,
2014

Patients with TD
have a significantly
higher healthcare
utilization rate and
costs compared with
non-TD patients.

Double-blind
placebocontrolled

Participants with a
DSM-IV diagnosis of
schizophrenia,
schizoaffective disorder,
or a mood disorder who
completed the 6-week
KINECT 3

The long term
safety and
tolerability of
Valbenazine was
favorable

Health care resource utilization
and costs for patients with
tardive dyskinesia. Journal of
Managed care & Specialty
pharmacy, 25(7), 810-816.
Factor, S. A., Remington, G.,
Comella, C. L., Correll, C. U.,
Burke, J., Jimenez, R., ... &
Christopher, F. O. (2017)
The effects of valbenazine in
participants with tardive
dyskinesia: results of the 1-year
KINECT 3 extension study. The
Journal of Clinical
Psychiatry, 78(9), 0-0. 5
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McEvoy, J., Gandhi, S. K.,
Rizio, A. A., Maher, S.,
Kosinski, M., Bjorner, J. B., &
Carroll, B. (2019)
Effect of tardive dyskinesia on
quality of life in patients with
bipolar disorder, major
depressive disorder, and
schizophrenia. Quality of Life
Research, 28(12), 3303-3312.
Othman, Z., Ghazali, M., Razak,
A. A., & Husain, M. (2013)

Crosssectional
survey

Descriptive
Analysis

The severity of Tardive
Dyskinesia
and Negative Symptoms are
Associated with Poor Quality of
Life in Schizophrenia
Patients. International Medical
Journal, 20(6), 677–680.
Ricciardi, L., Pringsheim, T.,
Barnes, T., Martino, D.,
Gardner, D., Remington, G.,
Addington,
D., Morgante, F., Poole, N.,
Carson, A., & Edwards, M.
(2019)

Systemic
Review

Patients at least age 18
with a confirmed
diagnosis of BD, MDD,
or SZ

Patients with TD
have a worse healthrelated quality of
life and social
withdrawal than
those without.

71 clinically stable aged
18 to 65 schizophrenia
patients with TD
recruited from HUSM or
HRPZ.

Quality of life was
negatively
associated with the
severity of TD and
negative symptoms.

Data from Cochrane
reviews, AAN
guidelines, and
individual studies

Data is limited on
TD treatment but
the best
management
strategy is
prevention.

Treatment recommendations for
Tardive Dyskinesia. Canadian
Journal of Psychiatry. Revue
Canadienne de
psychiatrie, 64(6), 388–399.
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APPENDIX F – Abnormal Involuntary Movement Scale
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